Fig. 2.

Intraperitoneal application of DJK-5 impaired MRSA cutaneous lesion formation. (a) Mice were injected with 6 mg/kg of DJK-5 or saline as control via intraperitoneal injection prior to receiving subcutaneous injection with bioluminescent MRSA USA300. Representative images capturing dermonecrotic abscess lesions were taken 72 h post-infection. (b) Lesion sizes were measured three days post-infection using a caliper, n = 24 saline, n = 17 DJK-5. (c) Bioluminescent bacteria were imaged using In Vivo Imaging System (IVIS) and quantified using Living Image® Software, n = 20 saline, n = 17 DJK-5. (d) Five days post-infection, bacteria were recovered from saline or DJK-5 treated animals and plated for enumeration, n = 12 saline, n = 10 DJK-5. Three independent experiments were conducted and all comparisons were made using unpaired t tests; **, p < 0.01; ***, p < 0.001.